Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4030 | Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 Wiki | 1.00 |
| drug4031 | Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The primary objectives of this study are: - To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Children (MIS-C), and - To determine immunologic mechanisms and immune signatures associated with disease spectrum and subsequent clinical course during the year of follow-up.
Description: Participants who experience Coronavirus Disease 2019 (COVID-19)-related death, rehospitalization or major complications after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) illness and/or multisystem inflammatory syndrome in children (MIS-C).
Measure: Proportion of Participants With Either COVID-19-Related Death, Rehospitalization, Major Complications after SARS-CoV-2 Illness and/or MIS-C at 6 Months Post Illness Presentation Time: 6 Months Post Illness Presentation (Enrollment)Description: Participants who experience Coronavirus Disease 2019 (COVID-19)-related death, rehospitalization or major complications after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) illness and/or multisystem inflammatory syndrome in children (MIS-C).
Measure: Proportion of Participants with Coronavirus Disease 2019 (COVID-19)-Related Death after Multisystem Inflammatory Syndrome in Children (MIS-C) at 1 Year Post Illness Presentation Time: 1 Year Post Illness Presentation (Enrollment)Description: The occurrence of death in participants regardless of relationship to Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Measure: All-Cause Mortality Time: 1 Year Post Illness Presentation (Enrollment)Description: The occurrence of SARS-CoV-2 related death in participants.
Measure: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mortality Time: 1 Year Post Illness Presentation (Enrollment)Description: Characterization of Participants who require: Hospitalization subsequent to enrollment as an outpatient for SARS-CoV-2/COVID-19 related illness and/or MIS-C, or Rehospitalization after discharge from their initial admission for SARS-CoV-2/COVID-19 related illness and/or MIS-C. Abbreviations: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Disease 2019 (COVID-19) Multisystem Inflammatory Syndrome in Children (MIS-C)
Measure: Hospitalization for Participants Enrolled as an Outpatient or Rehospitalization after First Admission in Hospitalized Participants Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of dysregulation involving the coagulation system by D-dimer laboratory test.
Measure: Coagulation Abnormality by D-Dimer Biomarker Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of dysregulation involving the coagulation system by fibrinogen laboratory test.
Measure: Coagulation Abnormality by Fibrinogen Biomarker Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of dysregulation involving the coagulation system by PT and PTT laboratory tests.
Measure: Coagulation Abnormality by Prothrombin Time (PT) and Activated Partial Thromboplastin Time (PTT) Biomarkers Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of dysregulation involving the coagulation system by INR laboratory test.
Measure: Coagulation Abnormality by International Normalised Ratio (INR) Biomarker Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of coronary artery abnormalities (e.g., by echocardiogram and, if performed for clinical indications, angiogram, as examples).
Measure: Coronary Artery Abnormalities Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Prevalence of pulmonary hypertension by echocardiogram and standard of care assessments.
Measure: Pulmonary Hypertension Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of cardiovascular system dysregulation by BNP laboratory test.
Measure: Cardiovascular System Dysregulation by B-type natriuretic peptide (BNP) Biomarker Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of cardiovascular system dysregulation by Troponin I laboratory test.
Measure: Cardiovascular System Dysregulation by Troponin I Biomarker Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of cardiac function by echocardiogram (Echo), a test that uses high frequency sound waves (ultrasound) to make pictures of the heart. The test is also referred to as a diagnostic cardiac ultrasound.
Measure: Cardiovascular System Dysregulation by Echocardiogram Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of cardiovascular system dysregulation(s) evaluated by standardized 12-lead electrocardiogram. ECG rhythms, intervals and voltages will be assessed. Cross reference: ECG and EKG are used interchangeably.
Measure: Cardiovascular System Dysregulation by Electrocardiogram (ECG) Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Pulmonary fibrosis (i.e., scarring) or other abnormalities detected by computerized tomography (CT) imaging.
Measure: Pulmonary Abnormalities Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization by pulmonary function tests (spirometry without bronchodilators).
Measure: Pulmonary Function Characteristics Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of kidney/metabolic function by serum creatinine and blood urea nitrogen (BUN) laboratory tests
Measure: Renal/Metabolic Biomarkers: Serum Creatinine and Blood Urea Nitrogen (BUN) Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of kidney/metabolic function by the estimated glomerular filtration rate (eGFR) calculated value, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Measure: Renal/Metabolic Biomarker: Estimated glomerular filtration rate (eGFR) Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of liver/metabolic function by the following laboratory tests: alkaline phosphatase alanine aminotransferase (ALT/SGPT) and aspartate aminotransferase (AST/SGOT).
Measure: Hepatic/Metabolic Biomarkers: Serum Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase ( ALT/SGPT)and Aspartate Aminotransferase (AST/SGOT) Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of liver/metabolic function by serum total bilirubin laboratory test.
Measure: Hepatic/Metabolic Biomarker: Total Bilirubin Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Characterization of neurologic sequelae of infection/disease.
Measure: Neurologic Abnormalities Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Identified by and characterized during standard of care assessments.
Measure: Other End Organ and/or functional abnormalities Occurring After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection/ Coronavirus Disease 2019 (COVID-19) and/or Multisystem Inflammatory Syndrome in Children (MIS-C) Time: Up to 1 Year Post Illness Presentation (Enrollment)Description: Assessment of health-related quality of life (HRQOL) after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection/ Coronavirus Disease 2019 (COVID-19) and/or multisystem inflammatory syndrome in children (MIS-C). The Pediatric Quality of Life Inventory is a series of assessment instruments designed to measure the health-related quality of life of children. The PedsQL 4.0 provides an opportunity for the assessment of both overall (generic) quality of life as well as disease-specific quality of life. The PedsQL 4.0 Generic Core Scales are appropriate for assessing health-related quality of life in both healthy and chronically ill children. The four scales making up this generic battery include Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items).
Measure: Health Related Quality of Life Time: Up to 1 Year Post Illness Presentation (Enrollment)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports